Wilsons Advisory is pleased to have acted as Joint Lead Manager to Antisense Therapeutics Ltd.'s (“Antisense”; ASX.ANP) recent $7.3 million capital raising.
Antisense is Melbourne-based biotechnology company, developing and commercialising antisense pharmaceuticals for large unmet markets in rare diseases.
The company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients. Following highly promising Phase II trial results, Antisense will use the proceeds of the funds to prepare for its upcoming Phase IIb European clinical trial of ATL1102 in DMD and other initiatives to advance its drug development strategy.
The placement had strong investor support from both new and existing shareholders. Richard Sherman, Head of Corporate Finance Origination at Wilsons Advisory said “We’re very pleased to have supported Antisense with this important capital raising. We are looking forward to continuing to support Antisense as it accelerates the advancement of ATL1102 into late stage clinical development for DMD”.
For more information contact:
Head of Corporate Finance, Rob Snow
rob.snow@wilsonsadvisory.com.au / (02) 8247 6645;
Head of Corporate Finance Origination, Richard Sherman richard.sherman@wilsonsadvisory.com.au / (03) 9640 3879
About Wilsons Advisory: Wilsons Advisory is a financial advisory firm focused on delivering strategic and investment advice for people with ambition – whether they be a private investor, corporate, fund manager or global institution. Its client-first, whole of firm approach allows Wilsons Advisory to partner with clients for the long-term and provide the wide range of financial and advisory services they may require throughout their financial future. Wilsons Advisory is staff-owned and has offices across Australia.
Disclaimer: This communication has been prepared by Wilsons Advisory and Stockbroking Limited (ACN 010 529 665; AFSL 238375) and/or Wilsons Corporate Finance Limited (ACN 057 547 323; AFSL 238383) (collectively “Wilsons Advisory”). It is being supplied to you solely for your information and no action should be taken on the basis of or in reliance on this communication. To the extent that any information prepared by Wilsons Advisory contains a financial product advice, it is general advice only and has been prepared by Wilsons Advisory without reference to your objectives, financial situation or needs. You should consider the appropriateness of the advice in light of your own objectives, financial situation and needs before following or relying on the advice. You should also obtain a copy of, and consider, any relevant disclosure document before making any decision to acquire or dispose of a financial product. Wilsons Advisory's Financial Services Guide is available at wilsonsadvisory.com.au/disclosures.
All investments carry risk. Different investment strategies can carry different levels of risk, depending on the assets that make up that strategy. The value of investments and the level of returns will vary. Future returns may differ from past returns and past performance is not a reliable guide to future performance. On that basis, any advice should not be relied on to make any investment decisions without first consulting with your financial adviser. If you do not currently have an adviser, please contact us and we would be happy to connect you with a Wilsons Advisory representative.
To the extent that any specific documents or products are referred to, please also ensure that you obtain the relevant disclosure documents such as Product Disclosure Statement(s), Prospectus(es) and Investment Program(s) before considering any related investments.
Wilsons Advisory and their associates may have received and may continue to receive fees from any company or companies referred to in this communication (the “Companies”) in relation to corporate advisory, underwriting or other professional investment services. Please see relevant Wilsons Advisory disclosures at www.wilsonsadvisory.com.au/disclosures.
